Research Article
An Obesity-Related FTO Variant and the Risk of Preeclampsia in a Finnish Study Population

Miira Klemetti,1, 2, 3 Leena M. Hiltunen,4 Sanna Heino,2 Seppo Heinonen,5 Eero Kajantie,6, 7 and Hannele Laivuori2, 3

1 Department of Obstetrics and Gynecology, Helsinki University Central Hospital, P.O. Box 140, 00029 Helsinki, Finland
2 Department of Medical Genetics, Haartman Institute, Biomedicum Helsinki, University of Helsinki, P.O. Box 63, 00014 Helsinki, Finland
3 Women’s Health Research Program, University of Helsinki, Helsinki, Finland
4 Department of Hemostasis, Finnish Red Cross Blood Service, Kivihaantie 7, 00310 Helsinki, Finland
5 Department of Obstetrics and Gynecology, Kuopio University Hospital, P.O. Box 1777, 70211 Kuopio, Finland
6 Diabetes Prevention Unit, National Institute of Health and Welfare, P.O. Box 30, 00271 Helsinki, Finland
7 Hospital for Children and Adolescents, Helsinki University Central Hospital, P.O. Box 281, 00029 Helsinki, Finland

Correspondence should be addressed to Miira Klemetti, miira.klemetti@helsinki.fi

Received 9 May 2011; Revised 31 August 2011; Accepted 31 August 2011

Academic Editor: Rosa Corcoy

Copyright © 2011 Miira Klemetti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Previous studies have demonstrated a common variant of the obesity and fat mass-related FTO gene, rs9939609, to be associated with obesity, type 2 diabetes, and elevated blood pressure. We investigated whether the FTO SNP rs9939609 is associated with the risk of preeclampsia (PE) in a Finnish study population. 485 women with prior PE and 449 women who had given birth after a normotensive pregnancy were genotyped (TaqMan) for the SNP rs9939609. The prevalences of genotypes AA, AT, and TT were 15%, 53%, and 32%, respectively, among the PE cases, and 16%, 47%, and 37%, respectively, among the controls (P = 0.199). We found no evidence of an association between the FTO SNP rs9939609 and PE. However, our cases were dominated by severe, early-onset PE. Thus, we are unable to exclude an association with the milder, later-onset form of the disease in which the role of maternal metabolic predisposition could be more significant.

1. Introduction

Along with the obesity pandemic, women of reproductive age are gaining weight [1]. Overweight and obesity predispose to various pregnancy complications, such as preeclampsia (PE) [2]. PE is a potentially life-threatening syndrome of hypertension, proteinuria, generalized vasoconstriction, and platelet consumption, complicating 2–6% of first pregnancies [3]. Its exact pathogenesis remains unclear, but both genetic and environmental factors seem to play a role. Studies have shown links between the pathologic characteristics of the metabolic syndrome, gestational diabetes and type 2 diabetes (T2DM), and those of PE (e.g., obesity, hyperinsulinemia, hypertriglyceridemia, thrombotic and proinflammatory changes, endothelial dysfunction, and sympathetic overactivity) [4–6]. Many of the metabolic abnormalities appear to persist several years postpartum [7–10]. In line with these findings, patients with prior PE seem to be at elevated risk of developing impaired glucose tolerance or T2DM in later life [11, 12].

Genome-wide association studies in several ethnic populations have shown a common variant of the highly polymorphic obesity and fat mass-related FTO gene, rs9939609 (T/A), located on chromosome 16q2, to be associated with obesity and T2DM [13, 14]. While the mechanisms of this association are not known, the effect of FTO variants on the risk of T2DM is mediated by the effect of FTO on the body-mass index (BMI). Recent studies have revealed linkages between FTO variants and gestational diabetes [15], the polycystic ovary syndrome (PCOS) [16] as well as the metabolic syndrome and hyperandrogenism in PCOS women [17, 18]. The A-allele of rs9939689 has also been
associated with elevated blood pressure in Finnish women and French Canadians [19, 20]. As PE is linked to many of the above-mentioned conditions associated with FTO variants, we decided to investigate whether the SNP rs9939609 is associated with the risk of PE in a Finnish study population.

2. Material and Methods

We genotyped the FTO SNP rs9939609 in 485 Finnish women with prior PE in a singleton pregnancy and 449 control women who had given birth after a normotensive singleton pregnancy. The subjects came from three different studies described below. All subjects provided a written informed consent, and all study protocols were approved by the appropriate local ethical committees. In addition, the approval of the Finnish Ministry of Social Affairs and Health was obtained for the population-based study (data set 1).

The diagnostic criteria of PE used are defined below separately for each study. Systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 110 mmHg was classified as severe PE. The criteria for severe PE used in this study do not include the severity of proteinuria as quantitative measurements of proteinuria were not available for all cases.

Prepregnancy weight and height were obtained from the antenatal care records, where they are in most cases recorded as reported by the mother at the first maternity clinic visit, usually before 12 weeks of gestation. Body mass index (BMI) was defined as the prepregnancy weight in kilograms divided by height in meters squared (kg/m²). BMI ≥ 25 kg/m² was classified as overweight and BMI ≥ 30 kg/m² as obese. Small-for-gestational age (SGA) was defined as relative birth weight under −2.0 SD units (Z score) according to Finnish standards [21].

2.1. Data Set 1: Finnish Population-Based Preeclampsia Study. The cases and controls for the population-based data set were identified by combining two national registers [22]. In Finland, pregnant women are registered in the National Register of Blood Group and Blood Group Antibodies of Pregnant Women at the Finnish Red Cross Blood Service, from which 100,000 consecutive pregnant women were identified during 1997-1998. Of these, 1084 had an International Classification of Diseases (ICD-10) code for PE or eclampsia in the National Hospital Discharge Register maintained by the National Research and Development Centre for Welfare and Health. First, 665 women with PE diagnosis were invited to the study, and 411 (62%) participated. After checking the case records and excluding multiple pregnancies, 226 cases with singleton pregnancies fulfilled the criteria for PE. In addition to PE patients, a random sample of women without pregnancy complications (n = 1930) were invited to the study, and 843 (44%) participated. Of these, 346 women with singleton full-term pregnancies without hypertensive complications, matched as closely as possible with the cases for the province of residence, parity, and maternal age, served as controls in this study. All participants were of Finnish ethnic origin, gave blood samples for the study, and filled out questionnaires to supplement the data obtained from medical records.

PE was defined as systolic blood pressure ≥ 140 mmHg and diastolic blood pressure ≥ 90 mmHg with new-onset proteinuria (0.3 g/l or ≥0.5 g/24 hours or dipstick ≥ + representing values ≥0.3 g/l) after 20 weeks of gestation in a previously normotensive woman (slightly modified from ACOG criteria) [22, 23]. The highest blood pressure values were recorded.

2.2. Data Set 2: Southern Finland Preeclampsia Study. Using the discharge records, we identified women who had developed severe PE and given birth in Helsinki University Central Hospital between January 1988 and April 1998 [24]. Patients with multiple pregnancies were excluded. Blood samples were collected between January 1997 and April 1998 after the index pregnancy. During the same period, blood samples were collected from control subjects with singleton deliveries in the same hospital after uncomplicated pregnancies. In total, 129 preeclamptic women and 103 normotensive healthy controls with no pregnancy complications were recruited. Among the PE cases, 102 women had a systolic blood pressure ≥160 mmHg and/or a diastolic blood pressure ≥110 mmHg, and 61 patients had proteinuria of at least 5 g per 24-hour urine collection. All subjects were of Finnish ethnic origin, lived in southern Finland, and had been healthy before their first pregnancy, without evidence of renal or autoimmune diseases. At 12 weeks postpartum, all women were normotensive, and proteinuria had disappeared.

The diagnostic criteria of PE used were systolic blood pressure ≥140 mmHg and diastolic blood pressure ≥90 mmHg with new-onset proteinuria (≥0.3 g/24 hours) after 20 weeks of gestation in a previously normotensive woman [24]. The blood pressure was confirmed by two measurements taken at least 6 hours apart.

2.3. Data Set 3: Eastern Finland Preeclampsia Study. The samples of this data set were collected retrospectively from women with prior PE when primiparous who delivered at Kuopio University Hospital between January 1994 and December 1998 [25]. PE patients were identified from the Birth Registry of the City of Kuopio, contacted by telephone, and asked to participate in the study and sign a consent form. Patients with multiple pregnancies were excluded. In total, samples obtained from 130 women with prior PE in a singleton pregnancy were analyzed.

In this study, PE was defined as the development of hypertension and new-onset proteinuria (≥300 mg of urinary protein per 24 hours). Hypertension was defined as ≥140 mmHg systolic and/or ≥90 mmHg diastolic pressure, when measured on two consecutive occasions at least 24 hours apart [26]. Women with essential hypertension were excluded from the study.

2.4. SNP Genotyping. The FTO SNP (rs9939609) was genotyped using an ABI TaqMan allele discrimination predesigned SNP genotyping assay (Applied Biosystems).
3. Results

3.1. Characteristics of the Study Subjects. The combined background characteristics of the three study populations used in this study are presented in Table 1. There was no significant difference in the mean age of PE cases and controls. Expectably, the cases had a higher mean BMI than the controls although the difference was statistically significant only among the primiparas. In addition, the cases delivered earlier and their infants had a lower birth weight. Pregestational and gestational diabetes were slightly more common among the primiparous PE cases than among the primiparous control women.

When the PE cases of the three data sets were studied separately, significant differences in the background characteristics and risk factors were found between the data sets. The mean BMI values among the PE cases in data sets 1, 2, and 3 were 24.3 kg/m², 22.4 kg/m², and 24.8 kg/m², respectively, with the difference between data set 2 and the other two data sets being statistically significant (P < 0.001). In data sets 1 and 2, the mean systolic blood pressure used to define PE in cases was similar, 170.2 mmHg and 170.9 mmHg, respectively, but in data set 3, it was significantly lower, 161.0 mmHg (P < 0.001). Correspondingly, the mean diastolic blood pressure values used to define PE in data sets 1 and 2 were 106.1 mmHg and 107.2 mmHg, but in data set 3, the mean was 102.9 mmHg (P = 0.016 and P = 0.002 for data set 3 versus data sets 1 and 2, resp.). The mean gestational age at delivery was higher among the PE cases of data set 1 (36.6 weeks gestation) compared with those of data sets 2 (34.4 weeks gestation) and 3 (35.1 weeks gestation) (P < 0.001 and P = 0.001, resp.). Also the relative birth weight was higher among the offspring of cases of data set 1 (~1.0 SD units) compared with those of data set 2 (~1.6 SD units) and data set 3 (~1.4 SD units) (P = 0.001 and 0.017, resp.).

3.2. Risk Factors of Preeclampsia. Well-established risk factors of PE such as BMI (odds ratio [OR] for each kg/m² increase in BMI = 1.07; 95% CI: 1.04, 1.11; P < 0.001), primiparity (OR = 1.37; 95% CI: 1.05, 1.79; P = 0.020), and pregestational diabetes (OR = 6.16; 95% CI: 1.38, 27.4; P = 0.017) were associated PE also in this study population when all three data sets were combined. When the data sets were analyzed separately, prepregnancy BMI was associated with PE (OR = 1.11; 95% CI: 1.06–1.15; P < 0.001) and severe PE defined by hypertensive criteria only (OR: 1.10; 95% CI: 1.06–1.16; P < 0.001) in data set 1 but not in data set 2 (OR = 0.95; 95% CI: 0.87, 1.03; P = 0.172; and OR = 0.963; 95% CI: 0.89, 1.05; P = 0.963, resp.).

Overall, 17.9% of all study subjects were overweight and 7.5% were obese. In data sets 1, 2, and 3, the percentages of overweight and obese patients were 19.1% and 7.0%, 12.1% and 4.3%, and 23.1% and 15.4%, respectively. No difference in the frequency of overweight or obesity was found between subjects homozygous for the A-allele of rs9939609 and those homozygous for the T-allele (P = 0.406 and P = 0.134, resp.). In the entire study population, each additional A-allele corresponded to an increase in BMI of 0.145 kg/m², but the result was statistically nonsignificant (95% CI: −0.245, 0.535, P = 0.446). Among the cases and the controls, the BMI effect per one A-allele was 0.082 kg/m² (P = 0.791, 95% CI: −0.526, 0.690) and 0.025 kg/m² (P = 0.923, 95% CI: −0.474, 0.523), respectively. In data sets 1, 2, and 3, the BMI-changes per each additional A-allele were 0.197 (95% CI: −0.291, 0.685; P = 0.427), −0.412 (95% CI: −1.043, 0.219, P = 0.200), and 1.409 (95% CI: −0.034, 2.852; P = 0.056), respectively. The mean BMI for the genotypes TT, AT, and AA were 23.2, 23.5, and 23.5 for data set 1, 23.1, 22.5, and 22.3 for data set 2 and 24.2, 24.9, and 27.5 for data set 3, respectively, with all differences between groups being statistically nonsignificant.

3.3. rs9939609 and Preeclampsia. The rs9939609 genotypes and allele frequencies among the PE cases and controls are presented in Table 2. The genotype distributions did not deviate from the Hardy-Weinberg equilibrium among the cases or the controls. No evidence of an association between SNP rs9939609 of FTO and PE was found in this study. The prevalences of genotypes AA, AT, and TT were 15%, 53%, and 32%, respectively, among the PE cases, and 16%,
Table 1: Background characteristics of the Finnish preeclampsia patients and control subjects from data sets 1, 2, and 3.

|                         | Primiparous (n = 321) | Multiparous (n = 164) | Primiparous (n = 264) | Multiparous (n = 185) | Primiparous | Multiparous |
|-------------------------|------------------------|------------------------|------------------------|------------------------|-------------|-------------|
|                        | N Mean SD              | N Mean SD              | N Mean SD              | N Mean SD              | P*          | P*          |
| Age (years)             | 321 28.0 5.4           | 164 31.8 5.2           | 264 27.6 4.7           | 185 31.0 4.9           | 0.381       | 0.177       |
| BMI (kg/m²)             | 309 23.7 4.4           | 163 24.4 4.4           | 261 22.4 3.3           | 183 23.4 3.7           | <0.001      | 0.055       |
| Systolic BP (mmHg)      | 315 167.0 18.4         | 154 169.6 17.1         | 80 118.6 9.0           | 22 119.1 11.9          | <0.001      | <0.001      |
| Diastolic BP (mmHg)     | 316 105.7 10.1         | 154 105.1 10.4         | 80 73.6 7.8            | 22 72.2 8.9            | <0.001      | <0.001      |
| Birth weight (g)        | 320 2400 934.6         | 162 2382.6 863.2       | 264 3537.8 404.0       | 185 3635.0 412.8       | <0.001      | <0.001      |
| Relative birth weight (SD) | 311 −1.3 1.3         | 160 −1.2 1.3           | 262 −0.2 0.8           | 183 0.0 0.8            | <0.001      | <0.001      |
| Gestational age at birth (weeks) | 315 35.7 3.9       | 164 35.5 3.5           | 264 39.9 1.5           | 185 40.0 1.2           | <0.001      | <0.001      |
| percentage              | N %                    | N %                    | N %                    | N %                    | P*          | P*          |
| Gestational diabetes    | 16 5.0                 | 7 4.3                  | 5 1.9                  | 12 6.5                 | 0.046       | 0.362       |
| Pregestational diabetes | 8 2.5                  | 5 3.0                  | 1 0.4                  | 1 0.5                  | 0.046       | 0.103       |

* Student’s t-test or Mann-Whitney test. ** Chi-square test or Fisher’s exact test.
Table 2: FTO SNP rs9939609 genotypes and allele counts among the Finnish preeclampsia patients and control subjects from data sets 1, 2, and 3.

| Genotypes   | Preeclampsia | Controls |
|-------------|--------------|----------|
|             | Primiparous  | Multiparous | Combined | Primiparous  | Multiparous | Combined | Primiparous  | Multiparous | Combined |
|             | n = 321     | n = 164    | n = 485   | n = 264    | n = 185    | n = 449   |
| AA          | 51          | 20         | 71        | 39         | 30         | 69        |
| AT          | 159         | 92         | 251       | 118        | 92         | 210       |
| TT          | 106         | 48         | 154       | 104        | 63         | 167       |
| N/A*        | 5           | 4          | 9         | 3          | 0          | 3         |

Alleles (frequency)

|          | Preeclampsia | Controls |
|----------|--------------|----------|
|          | Primiparous  | Multiparous | Combined | Primiparous  | Multiparous | Combined |
| A        | 261 (0.41)   | 132 (0.41) | 393 (0.41) | 196 (0.38)   | 152 (0.41)  | 348 (0.39) |
| T        | 371 (0.59)   | 188 (0.59) | 559 (0.59) | 326 (0.62)   | 218 (0.59)  | 544 (0.61) |

* Genotyping failed.
** Chi-square test.

Table 3: The odds ratios (95% CI) for preeclampsia (PE). Severe PE and small-for-gestational age (SGA) associated with maternal FTO SNP rs9939609 AA and AT genotypes as well as with each additional A allele (unadjusted and adjusted) in a Finnish study population.

| Covariates                      | OR (95% CI) for outcome |
|---------------------------------|-------------------------|
|                                 | PE reference            | Severe PE** reference | SGA reference |
|                                 |                         |                        |               |
| TT AT*                           | 1.30 (0.97.1.72)        | 1.31 (0.95.1.79)       | 1.05 (0.70.1.57) |
| AA*                             | 1.12 (0.75.1.66)        | 0.98 (0.62.1.53)       | 0.83 (0.45.1.50) |
| Per A-allele, unadjusted*        | 1.10 (0.91.1.33)        | 1.05 (0.85.1.30)       | 0.94 (0.72.1.24) |
| Per A-allele, adjusted for log-transformed BMI* | 1.09 (0.89.1.32) | 1.04 (0.84.1.28) | 0.91 (0.69.1.21) |
| Per A-allele, adjusted for log-transformed BMI, age and diabetes* | 1.09 (0.90.1.32) | 1.03 (0.83.1.28) | 0.90 (0.68.1.20) |

* Binary logistic regression analysis.
** Nonsevere PE cases excluded.

47%, and 37%, respectively, among the controls (P = 0.199). The crude and adjusted odds ratios for the association of FTO with PE, severe PE, and the delivery of a small-for-gestational-age (SGA) infant are presented in Table 3.

4. Discussion

Although overweight is a major risk factor of pregnancy-induced hypertension and PE [2], we were unable to demonstrate an association between the obesity-predisposing rs9939609 of FTO and PE in this study. To the best of our knowledge, no reports on this subject have been published previously.

The study population used in this study can be considered fairly representative of the Finnish population as it is composed of a population-based sample as well as subjects recruited from hospitals with geographically based catchment areas in both Eastern and Southern Finland. The A-allele frequency among this study population is somewhat higher than that reported by another Finnish study [27] but in line with the frequency demonstrated in other European populations [28].

One of the weaknesses of the data sets used in this study was the lack of information on lifestyle factors, which could have influenced the association of rs9939609 with BMI. Past studies regarding the interaction of physical activity and the effect of the FTO genotype on BMI have been somewhat conflicting. Karasawa et al. [29] studied the effect of energy expenditure for moderate to high-intensity physical activity on the association of rs9939609 of the FTO with obesity. The group found BMI to be significantly higher and obesity more frequent in the group with genotype AA and low physical activity, but not in the group with genotype AA and high physical activity. Other researchers have also reported the effect of FTO on obesity to be exacerbated by low physical activity [30–33]. On the contrary, a study by Jonsson et al. [34] with a sample of 15925 Swedish and 2511 Finnish nondiabetic adults did not support the notion that physical activity modifies the effects of the FTO rs9939609 variant on obesity. Furthermore, Lappalainen et al. [35] found no association between FTO variant and the magnitude of weight reduction achieved by a long-term lifestyle intervention in the Finnish Diabetes Prevention Study (DPS) among middle-aged subjects with impaired glucose tolerance.

The study population consisted entirely of women of reproductive age. However, the lack of male study subjects should not be behind the lack of BMI association as previous studies have consistently shown the A-allele of rs9939609 to predispose to obesity independent of sex [13].
studies that have reported sex differences have demonstrated a stronger effect among women [35, 36]. It is unlikely that the mean age of the study populations would conceal the BMI-effect because the association of the rs9939609 of FTO with BMI has been clearly shown among both children and adults [13, 28]. Hardy et al. [37] have, however, demonstrated the effect to peak at 20 years and then weaken with progressing age.

The present study population was relatively lean, with the mean BMIs ranging from 22.4 to 24.8 in the three data sets analysed. However, the prepregnancy body weight was self-reported by the study subjects and thus might be somewhat underreported. Nevertheless, the leanness of the study population might be one factor contributing to the lack of association of FTO with BMI in this study. This is supported by the fact that the FTO-BMI effect per one A-allele was the largest and approached statistical significance among the subjects of data set 3, which included more overweight and obese subjects than the other data sets. The results of Jacobsson et al. [33] also suggested that the impact of FTO on obesity may be less prominent in lean populations. On the other hand, the FTO-BMI association was clear in the ALSPAC study population, which was composed of women of reproductive age with a mean BMI comparable to the one reported in the present study [28].

The differences in the background characteristics of the three PE data sets could explain why no association was demonstrated between the rs9939609 of FTO and BMI or PE in this study. The PE cases in data set 2 suffered predominantly from the severe, earlier-onset form of PE with high proteinuria, whereas in data sets 1 and 3, the severity of PE among the cases varied. In data set 2, the cases were the leanest, BMI was not associated with an increased risk of PE, and the gestational age at delivery was the lowest. This is in line with the hypothesis that the early-onset PE is characterized by abnormal placentaion and a stronger genetic component, while the role of maternal metabolic predisposition is more significant in the late-onset form of the disease [38].

5. Conclusions

We found no evidence of an association between the fat-mass-associated SNP rs9939609 and PE. It is possible that risk factors other than obesity dominate among patients manifesting severe, early-onset PE compared to those with a milder, later-onset form of the disease. Our cases were dominated by the more severe end of the disease spectrum, and therefore we are unable to exclude an association in particular with the less severe, later-onset forms of the disease. The possible association of the fat-mass-associated SNP rs9939609 and PE should be further investigated with larger sample sizes and with possibilities of stratifying the sample according to the degree of severity and the gestation weeks at the onset of the disease.

Conflict of Interests

The authors have no conflict of interests.

Acknowledgments

Support for this work has been provided by Aarne and Aili Turunen Foundation (LH), The Academy of Finland (HL, EK), The Finnish Medical Foundation (HL), The Finnish-Norwegian Medical Foundation (LH), Helsinki University Central Hospital (HL), Päiviikki and Sakari Sohlfberg Foundation (HL, EK), University of Helsinki (HL), Jane and Aatos Erkko Foundation (HL), Finnish Foundation of Pediatric Research (EK), Juho Vainio Foundation (EK), Novo Nordisk Foundation (EK), Research Foundation of Orion Corporation (LH), Research Fund of FRCBS (LH), Sigrid Jusélius Foundation (EK), Helsinki University Research Foundation (MK), and Paulo Foundation (MK). The authors want to thank Ms. Hanna Nurmi for technical assistance in genotyping.

References

[1] K. Raatikainen, N. Heiskanen, and S. Heinonen, “Transition from overweight to obesity worsens pregnancy outcome in a BMI-dependent manner,” Obesity, vol. 14, no. 1, pp. 165–171, 2006.
[2] T. E. O’Brien, J. G. Ray, and W. S. Chan, “Maternal body mass index and the risk of preeclampsia: a systematic overview,” Epidemiology, vol. 14, no. 3, pp. 368–374, 2003.
[3] J. M. Roberts and C. W. Redman, “Pre-eclampsia: more than pregnancy-induced hypertension,” The Lancet, vol. 341, no. 8858, pp. 1447–1451, 1993.
[4] R. Kaaja, M. Tikkanen, L. Viinikka, and O. Ylikorkala, “Serum lipoproteins, insulin, and urinary prostanooid metabolites in normal and hypertensive pregnant women,” Obstetrics and Gynecology, vol. 85, no. 3, pp. 335–336, 1995.
[5] R. Kaaja, H. Laivuori, M. Laakso, M. J. Tikkanen, and O. Ylikorkala, “Evidence of a state of increased insulin resistance in preeclampsia,” Metabolism, vol. 48, no. 7, pp. 892–896, 1999.
[6] C. G. Solomon and E. W. Seely, “Brief review: hypertension in pregnancy a manifestation of the insulin resistance syndrome?” Hypertension, vol. 37, no. 2, pp. 232–239, 2001.
[7] H. Laivuori, M. J. Tikkanen, and O. Ylikorkala, “Hyperinsulinemia 17 years after preeclamptic first pregnancy,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 8, pp. 2908–2911, 1996.
[8] C. A. Hubel, S. Snaedal, R. B. Ness et al., “Dyslipoproteinemia in postmenopausal women with a history of eclampsia,” British Journal of Obstetrics and Gynaecology, vol. 107, no. 6, pp. 776–784, 2000.
[9] P. K. Agatisa, R. B. Ness, J. M. Roberts, J. P. Costantino, L. H. Kuller, and M. McLaughlin, “Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk,” American Journal of Physiology, vol. 286, no. 4, pp. H1389–H1393, 2004.
[10] K. H. Lampinen, M. Rönöback, R. J. Kaaja, and P. H. Groop, “Impaired vascular dilatation in women with a history of preeclampsia,” Journal of Hypertension, vol. 24, no. 4, pp. 751–756, 2006.
[11] G. Libby, D. J. Murphy, N. F. McLanet al., “Pre-eclampsia and the later development of type 2 diabetes in mothers and their children: an intergenerational study from the Walker cohort,” Diabetologia, vol. 50, no. 3, pp. 523–530, 2007.
Journal of Pregnancy

[12] J. Saramies, S. Koinan-Kiukaanniemi, M. Koiranen, J. Jokela, V. B. Meyer-Rochow, and M. Timonen, “Late pregnancy blood pressure in nulliparas and subsequent abnormal glucose tolerance,” *Diabetes Research and Clinical Practice*, vol. 71, no. 2, pp. 220–224, 2006.

[13] K. A. Fawcett and I. Barroso, “The genetics of obesity: FTO leads the way,” *Trends in Genetics*, vol. 26, no. 6, pp. 266–274, 2010.

[14] R. J. F. Loos and C. Bouchard, “*FTO* gene associates to metabolic syndrome in women with polycystic ovary syndrome,” *Diabetologia*, vol. 51, no. 7, pp. 1153–1158, 2008.

[15] J. Lauenborg, N. Grarup, P. Damm et al., “Common type 2 diabetes risk gene variants associate with gestational diabetes,” *Journal of Clinical Endocrinology and Metabolism*, vol. 94, no. 1, pp. 145–150, 2009.

[16] T. M. Barber, A. J. Bennett, C. J. Groves et al., “Association of variants in the fat mass and obesity associated (FTO) gene with polycystic ovary syndrome,” *Obesity Reviews*, vol. 9, no. 3, pp. 246–250, 2008.

[17] R. Attaoua, S. Ait El Mkadem, S. Radian et al., “*FTO* gene associates to metabolic syndrome in women with polycystic ovary syndrome,” *Biochemical and Biophysical Research Communications*, vol. 373, no. 2, pp. 230–234, 2008.

[18] E. Wehr, N. Schweighofer, R. Möller, A. Giuliani, T. R. Pieber, and B. Obermayer-Pietsch, “Association of FTO gene with hyperandrogenemia and metabolic parameters in women with polycystic ovary syndrome,” *Metabolism*, vol. 59, no. 4, pp. 575–580, 2010.

[19] T. Lappalainen, M. Kolehmainen, U. S. Schwab et al., “Association of the FTO gene variant (rs9939609) with cardiovascular disease in men with abnormal glucose metabolism—the Finnish Diabetes Prevention Study,” *Nutrition, Metabolism and Cardiovascular Diseases*, 2010.

[20] Z. Pausova, C. Syme, M. Abrahamowicz et al., “A common variant of the *FTO* gene is associated with not only increased adiposity but also elevated blood pressure in French canadians,” *Circulation*, vol. 2, no. 3, pp. 260–269, 2009.

[21] J. Piikala, T. Hakala, P. Voutilainen, and K. Raivio, “Characteristic of recent fetal growth curves in Finland,” *Duodecim*, vol. 105, no. 18, pp. 1540–1546, 1989 (Finnish).

[22] L. Hiltunen, H. Laivuori, A. Rautanen et al., “Blood group AB and factor V Leiden as risk factors for pre-eclampsia: a population-based nested case-control study,” *Thrombosis Research*, vol. 124, no. 2, pp. 167–173, 2009.

[23] ACOG Committee on Obstetric Practice, “ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia,” *International Journal of Gynaecology and Obstetrics*, vol. 77, no. 1, pp. 67–75, 2002.

[24] H. Laivuori, R. Kaaja, O. Ylikorkala, T. Hiltunen, and K. Kontula, “677 C > T polymorphism of the methylenetetrahydrofolate reductase gene and preeclampsia,” *Obstetrics and Gynecology*, vol. 96, no. 2, pp. 277–280, 2000.

[25] T. Saarela, M. Hiltunen, S. Helisalmi, S. Heinonen, and M. Laakso, “Tumour necrosis factor-α gene haplotype is associated with pre-eclampsia,” *Molecular Human Reproduction*, vol. 11, no. 6, pp. 437–440, 2005.

[26] E. J. Roccella, “Report of the national high blood pressure education program working group on high blood pressure in pregnancy,” *American Journal of Obstetrics and Gynecology*, vol. 183, supplement 1, pp. S1–S22, 2000.

[27] I. Surakka, K. Kristiansson, V. Anttila et al., “Founder population-specific HapMap panel increases power in GWA studies through improved imputation accuracy and CNV tagging,” *Genome Research*, vol. 20, no. 10, pp. 1344–1351, 2010.

[28] T. M. Frayling, N. J. Timpson, M. N. Weedon et al., “A common variant in the *FTO* gene is associated with body mass index and predisposes to childhood and adult obesity,” *Science*, vol. 316, no. 5826, pp. 889–894, 2007.

[29] S. Karasawa, M. Daimon, S. Sasaki et al., “Association of the common fat mass and obesity associated (*FTO*) gene polymorphism with obesity in a Japanese population,” *Endocrine Journal*, vol. 57, no. 4, pp. 293–301, 2010.

[30] C. H. Andreasen, K. L. Stender-Petersen, M. S. Mogensen et al., “Low physical activity accentuates the effect of the *FTO* rs9939609 polymorphism on body fat accumulation,” *Diabetes*, vol. 57, no. 1, pp. 95–101, 2008.

[31] E. Kamperotis, M. J. Mitchell, T. L. Pollin et al., “Physical activity and the association of common *FTO* gene variants with body mass index and obesity,” *Archives of Internal Medicine*, vol. 168, no. 16, pp. 1791–1797, 2008.

[32] S. Caucci, F. Stutzmann, C. Cavalcanti-Proença et al., “Combined effects of MC4R and *FTO* common genetic variants on obesity in European general populations,” *Journal of Molecular Medicine*, vol. 87, no. 5, pp. 537–546, 2009.

[33] J. A. Jacobsson, U. Risérus, T. Axelsson, L. Lannfelt, H. B. Schioth, and R. Fredriksson, “The common FTO variant rs9939609 is not associated with BMI in a longitudinal study on a cohort of Swedish men born 1920–1924,” *BMC Medical Genetics*, vol. 10, article 131, 2009.

[34] A. Jonsson, F. Renström, V. Lyskenko et al., “Assessing the effect of interaction between an *FTO* variant (rs9939609) and physical activity on obesity in 15,925 Swedish and 2,511 Finnish adults,” *Diabetologia*, vol. 52, no. 7, pp. 1334–1338, 2009.

[35] T. J. Lappalainen, A. M. Tolppanen, M. Kolehmainen et al., “The common variant in the *FTO* gene did not modify the effect of lifestyle changes on body weight: the finnish diabetes prevention study,” *Obesity*, vol. 17, no. 4, pp. 832–836, 2009.

[36] J. A. Jacobsson, P. Danielsson, V. Svensson et al., “Major gender difference in association of *FTO* gene variant among severely obese children with obesity and obesity related phenotypes,” *Biochemical and Biophysical Research Communications*, vol. 368, no. 3, pp. 476–482, 2008.

[37] R. Hardy, A. K. Wills, A. Wong et al., “Life course variations in the associations between *FTO* and MC4R gene variants and body size,” *Human Molecular Genetics*, vol. 19, no. 3, Article ID ddp504, pp. 545–552, 2010.

[38] C. B. M. Oudejans, M. Dijk, M. Oosterkamp, A. Lachmeijer, and M. A. Blankenstein, “Genetics of preeclampsia: paradigm shifts,” *Human Genetics*, vol. 120, no. 5, pp. 607–612, 2007.